Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONNECTION-II neoadjuvant CAPOX in microsatellite-stable high-risk stage II and stage III colon cancer
NL-OMON53082Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by University Medical Center Utrecht. Primary endpoint: Pathological tumor response by Dworak TRG. Started Feb 2020; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on NL-OMON53082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53082.